Head-to-head evidence
Cabotegravir vs Elvitegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Cabotegravir · Vocabria / Cabenuva / Apretude
Marketed by ViiV Healthcare
NCT02720094 · Phase 2/3 · completed
The trial randomized 4,570 participants to cabotegravir or active-controlled TDF/FTC treatment and used quadruple blinding of participants, clinicians, investigators, and outcome assessors. Its hard clinical primary efficacy endpoint—documented incident HIV infection—was met, with 13 versus 39 infections and a hazard ratio of 0.340 (95% CI 0.18–0.62; p=0.0005).
Next expected readout: October 2026 · NCT05660980 (registry estimate)
Elvitegravir · Stribild / Genvoya (component)
Marketed by Gilead Sciences
NCT00708162 · Phase 3 · completed
This was a randomized, triple-blind (participant, care provider, investigator), double-dummy, active-controlled phase 3 trial in 724 treatment-experienced HIV patients, comparing elvitegravir with raltegravir, both given with an optimized background regimen. The primary endpoint, confirmed HIV-1 RNA <50 copies/mL at week 48, was met as a non-inferiority result: 59.0% with elvitegravir vs 57.8% with raltegravir, with the 95% confidence interval for the difference (-6.0 to 8.2) falling entirely within the prespecified 10% margin. The trial was adequately powered (planned 700 participants, 85% power for non-inferiority).
Next expected readout: March 2034 · NCT06337032 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir's landscape · Elvitegravir's landscape